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Abstract
Background: Identification of patients with oral dysplasia at high risk of cancer development and oral squamous
cell carcinoma (OSCC) at increased risk of disease recurrence will enable rigorous personalized treatment. Regulated
intramembranous proteolysis of Epithelial cell adhesion molecule (EpCAM) resulting in release of its intracellular
domain Ep-ICD into cytoplasm and nucleus triggers oncogenic signaling. We analyzed the expression of Ep-ICD in
oral dysplasia and cancer and determined its clinical significance in disease progression and prognosis.
Methods: In a retrospective study, immunohistochemical analysis of nuclear and cytoplasmic Ep-ICD and EpEx
(extracellular domain of EpCAM), was carried out in 115 OSCC, 97 oral dysplasia and 105 normal oral tissues, correlated
with clinicopathological parameters and disease outcome over 60 months for oral dysplasia and OSCC patients.
Disease-free survival (DFS) was determined by Kaplan-Meier method and multivariate Cox regression analysis.
Results: In comparison with normal oral tissues, significant increase in nuclear Ep-ICD and membrane EpEx was
observed in dysplasia, and OSCC (p = 0.013 and < 0.001 respectively). Oral dysplasia patients with increased overall Ep-ICD
developed cancer in short time period (mean = 47 months; p = 0.044). OSCC patients with increased nuclear Ep-ICD and
membrane EpEx had significantly reduced mean DFS of 33.7 months (p = 0.018).
Conclusions: Our study provided clinical evidence for Ep-ICD as a predictor of cancer development in patients with oral
dysplasia and recurrence in OSCC patients, suggesting its potential utility in enhanced management of those patients
detected to have increased risk of progression to cancer and recurrence in OSCC patients.
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Background
Head and neck cancer is the sixth most prevalent
cancers accounting for approximately 600,000 new cases
annually worldwide [1]. Oral squamous cell carcinoma
(OSCC) is the major subtype of head and neck cancer
and accounts for two-thirds of the cases occurring in
least developed countries [2]. OSCCs are often preceded
by development of clinically distinct oral lesions; on an
average about one percent of oral lesions transform into
cancer annually [3, 4]. Histologic assessment of a biopsy
with evidence of dysplasia is used for determining the
risk of malignant transformation; increasing grade of
dysplasia (mild/moderate/severe) has been associated
with a high rate of malignant transformation. However,
dysplasia grading is subjective, not often associated with
malignant transformation; some dysplastic lesions may
remain static or even regress, while the non-dysplastic
lesions may occasionally become malignant. Accurate
assessment of oral dysplasia and identification of lesions
at high risk of malignant transformation remains a major
clinical challenge and is of immense importance for
identifying patients in whom early intervention will lead
to more effective disease management. The key to early
detection and effective management of the disease lies in
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better understanding of the molecular mechanisms im-
plicated in malignant transformation of oral lesions with
dysplasia. Furthermore, despite improvements in treat-
ment strategies the prognosis of OSCC patients remains
largely unsatisfactory, due to loco-regional recurrence.
The 5-year survival rates are about 50 %, and the prog-
nosis of advanced cases has not improved much over the
past 4 decades [2]. At present, the most important prog-
nostic factors include histological tumor grade, stage,
depth of tumor invasion and involvement of regional
lymph nodes at the time of diagnosis.
Epithelial cell adhesion molecule (EpCAM) is a trans-
membrane glycoprotein expressed in several human epi-
thelial tissues and frequently overexpressed in cancer,
progenitor, and stem cells [5]. EpCAM consists of an
extracellular epidermal growth factor-like (EGF) domain
(EpEx), thyroglobulin domain, transmembrane region,
and a short intracellular domain (Ep-ICD) [6, 7]. In nor-
mal cells, EpCAM appears to be sequestered in tight
junctions and is therefore less accessible to antibodies,
whereas in cancer cells it is widely distributed on the cell
surface and has therefore been explored as a surface-
binding site for therapeutic antibodies [8–11]. EpCAM
is involved in cell signaling, migration, proliferation, cell
cycle regulation, and cancer metastasis. and has been
widely investigated for its diagnostic and therapeutic po-
tential as it is expressed in the majority of human epithelial
cancers, including breast, colon, esophageal, gastric, hep-
atic, head and neck, prostate, pancreas, ovarian and lung
cancer [12–23]. Increased EpCAM expression has been
found to be a poor prognostic marker in breast and gall
bladder carcinomas [24, 25]. In contrast EpCAM expres-
sion in colorectal and gastric cancer is associated with
favorable prognosis [26, 27]. This paradoxical association
of EpCAM expression with prognosis in different cancers
is supported by functional studies of EpCAM biology using
in vitro and in vivo cancer models as well. Taken together
these studies suggest that the impact of EpCAM expres-
sion in human cancers is likely to be context dependent
[28]. EpCAM expression based assay has been FDA ap-
proved and widely used to detect circulating tumor cells in
breast cancer [29]. Due to its high-expression and asso-
ciation with poor prognosis, EpCAM has been widely
explored as a potential target for antibody-based im-
munotherapies [30]. EpCAM expression has been used
to predict response to anti-EpCAM antibodies in breast
cancer patients [30–32]. Surprisingly clinical trials of anti-
EpCAM antibodies targeting the EpEx domain have shown
limited efficacy [31, 33]. These paradoxical outcomes are
potentially explainable by the regulated intramembra-
nous proteolysis of EpCAM, resulting in oncogenic
signaling by its intracellular domain, Ep-ICD [34]. Pre-
viously, we reported accumulation of Ep-ICD is fre-
quently detected in ten epithelial cancers, including breast
and prostate [35, 36]. In thyroid carcinomas nuclear Ep-
ICD (Ep-ICDNuc) accumulation predicted poor prognosis
and was elevated in patients with anaplastic tumors [36].
Recently, a dynamic expression of EpCAM was reported
in esophageal cancer throughout tumor progression [16].
We hypothesized that alterations in Ep-ICD and EpEx
sub-cellular localization in membrane, cytoplasm and
nucleus could influence oral cancer pathogenesis and
may correlate with clinical outcome in these patients. In
this study, we determined the clinical significance of
alterations in expression and sub-cellular localization of
Ep-ICD and EpEx protein in oral tumorigenesis.
Methods
Study design
This retrospective study of Ep-ICD and EpEx using
OSCC and dysplasia patients’ tissue blocks stored in the
archives of Department of Pathology and Laboratory
Medicine and their anonymized clinical data was ap-
proved by the Mount Sinai Hospital (MSH) Research
Ethics Board, Toronto, Canada, prior to commencement.
The study was conducted according to the Reporting
Recommendations for Tumor Marker prognostic studies
(REMARK) guidelines and a retrospectively written re-
search, pathological evaluation, and statistical plan [37].
The patients granted informed written consent for their
tissue samples to be archived and used for research pur-
poses and publication of research findings.
Patients
Patient demographic, clinical, and pathological data
were recorded in a pre-designed Performa as described
previously [38].
Inclusion criteria
Patients with histopathological evidence of dysplasia or
squamous cell carcinoma of the oral cavity and a known
clinical outcome were inducted into the study.
Exclusion criteria
Patients diagnosed with dysplasia or squamous cell car-
cinoma of the oral cavity but with no available follow-up
data or patients diagnosed with dysplasia concomitant
with OSCC at the first visit were excluded from the study.
Specimen characteristics
The patients’ charts with clinico-pathological diagnosis of
OSCC from 2000 to 2008 were retrospectively reviewed to
obtain the clinical information and follow-up data in the
Department of Pathology, MSH. Information regarding
gender, age, site of lesions at the time of the initial diag-
nosis of dysplasia or OSCC was documented in the
clinical database. Following the above inclusion and ex-
clusion criteria, archived tissue specimens of OSCC
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patients (n = 115, median age: 61 years; range: 30–92 years)
undergoing curative cancer surgery during the period
2000–2008 were inducted into this study and 105 normal
tissues and 97 oral dysplasia were also obtained from
the archived tissue bank at MSH, Canada. All OSCC pa-
tients were treated as per the National Comprehensive
Cancer Network (NCCN) guide lines for head and neck
cancers [38].
Survival data
Malignant transformation versus non-transformation of
oral dysplastic lesions was considered to be the clinical
outcome of the patients with oral dysplasia. Follow-up
period was defined as the interval from the time when
patient underwent first biopsy to the non-transformation
at last consultation (for censored observations) or to
cancer development (for uncensored observations). Dys-
plasia patients were monitored for a maximum period of
60 months (mean 36.4 months and median 38 months).
Dysplasia to cancer development was observed in 22 of
97 (23 %) patients.
After completion of primary treatment OSCC patients
were followed up for up to 60 months (mean 32.8 months
and median 29.5 months). Notably, recurrence was ob-
served in 28 % patients. Disease-free survivors were de-
fined as patients free from clinical and radiological
evidence of local, regional, or distant relapse at the
time of the last follow-up. In the current study, recur-
rence of the cancer versus no recurrence of OSCC was
considered to be the clinical outcome of the patients.
Follow-up period was defined as the interval from the
time when patient underwent first surgery to recurrence
of cancer (for uncensored observations) or no recurrence
at last consultation (for censored observations).
Immunohistochemistry (IHC)
The histopathologic diagnosis of all cases were re-
examined by the oral pathologists at MSH. Tissue micro-
arrays (TMAs) were constructed using 100 of 115 OSCCs,
99 of 105 normal oral tissues and 95 of 97 oral dysplasias
as reported [39], while the remaining tissues were used as
individual sections for immunostaining. Formalin-fixed
paraffin embedded sections (4 μm thickness) were used
for Ep-ICD and EpEx immunostaining as described [28].
In brief, for EpEx following deparaffinization and rehydra-
tion, antigen retrieval was carried out using a microwave
oven in 0.01 M citrate buffer, pH 3.0 and endogenous per-
oxidase activity was blocked by incubating the tissue sec-
tions in hydrogen peroxide (0.3 %, v/v) for 20 min. For
Ep-ICD, the tissue sections were de-paraffinized by baking
at 62 °C for 1 h in vertical orientation, treated with xylene
and graded alcohol series, and the non-specific binding
was blocked with normal horse or goat serum. Rabbit
anti-human Ep-ICD monoclonal antibody from Epitomics
Inc. (Burlingame, CA) was used. The α-Ep-ICD antibody
1144 has been used in our previous study of Ep-ICD ex-
pression in thyroid carcinoma and other epithelial cancers
[36]. Anti-EpCAM monoclonal antibody EpEx (MOC-31,
AbD Serotec, Oxford, UK) recognizes an extracellular
component (EGF1 domain- aa 27–59) in the amino-
terminal region [40]. The sections were incubated with ei-
ther α-Ep-ICD rabbit monoclonal antibody 1144 (dilution
1:1500) or mouse monoclonal antibody MOC-31 (dilution
1:200) for 60 min, followed by biotinylated secondary anti-
body (goat anti-rabbit or goat anti-mouse) for 20 min.
The sections were finally incubated with VECTASTAIN
Elite ABC Reagent (Vector Laboratories, Burlington,
ON, Canada) and diaminobenzidine was used as the
chromogen. Tissue sections were then counterstained
with hematoxylin. Negative controls comprised of oral
tissue sections incubated with isotype specific IgG in
place of the primary antibody, and positive controls
(colon cancer tissue sections known to express Ep-ICD)
were included with each batch of staining for both Ep-ICD
and EpEx.
Evaluation of immunohistochemical staining
Each TMA slide or individual tissue section was evalu-
ated for Ep-ICD and EpEx immunoreactivity using a
semi-quantitative scoring system for both staining inten-
sity and the percentage of positive epithelial cells as
described [39]. Immunopositive staining was evaluated
in randomly selected five areas of the tissue section. For
Ep-ICD and EpEx protein expression, sections were
scored as positive if epithelial cells showed immuno-
staining in the nucleus/cytoplasm when observed inde-
pendently by three of us, who were blinded to the
clinical outcome (slides were coded and the scorers did
not have prior knowledge of local tumor burden, lym-
phonodular spread, and grading of tissue samples). The
tissue sections were scored based on the % of immuno-
stained cells as: 0–10 % = 0; > 10–30 % = 1; > 31–50 % =
2; > 51–70 % = 3 and > 71–100 % = 4. Sections were also
scored semi-quantitatively on the basis of staining inten-
sity as negative = 0; mild = 1; moderate = 2; intense = 3.
Finally, a total score was obtained by adding the score of
percentage positivity and intensity therefore giving a score
range from 0 to 7 [39]. We also we calculated the final
scores based on the multiplication of the two factors:
score of percentage positivity and the intensity of each of
the tissue section, and performed the statistical analysis.
Each tissue section was scored for cytoplasmic Ep-ICD
(Ep-ICDCyt) and Ep-ICDNuc as well as for membrane EpEx
(EpEXMem) following both these scoring methods.
Statistical analyses
The immunohistochemical data were subjected to statis-
tical analysis with SPSS 22.0 software (SPSS, Chicago, IL)
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as described previously [41]. A two-tailed p-value was
used in all analyses and a p-value < 0.05 was considered
statistically significant. Chi-square analysis was used to
determine the relationship between Ep-ICD and EpEx ex-
pression and the clinicopathological parameters. Disease-
free survival was analyzed by the Kaplan-Meier method
and multivariate Cox regression. Hazard ratios (HR), 95 %
confidence intervals (95 % CI), and p-values were esti-
mated using the log-rank test. Disease-free survival or
clinical recurrence was considered to be the endpoint of
the study. The cut-offs for statistical analysis were based
upon the optimal sensitivity and specificity obtained from
the Receiver operating curves as described [35]. For the
IHC total score obtained by adding the score of percent-
age positivity and intensity for Ep-ICDNuc, an IHC score
cut-off value of ≥ 2 was defined as immunopositive for all
tissues analyzed for statistical analysis. Ep-ICDCyt posi-
tivity was considered positive with an IHC cut-off value
of ≥ 4. EpExMem positivity was defined as EpExMem IHC
score of ≥ 2. A cut-off value of ≥ 3 was used for the
combination of Ep-ICDNuc and EpExMem positivity. For
oral dysplasia, the overall Ep-ICD positivity was defined
as the sum of Ep-ICDNuc + Ep-ICDCyt with a cut-off
value of ≥ 6. For the IHC scores based on the multipli-
cation of the score of percentage positivity and the in-
tensity of each of the tissue section, the cut-offs for
positivity were defined as - Ep-ICDNuc ≥1, Ep-ICDCyto ≥ 3
and EpExMem ≥ 1.
Results
The clinicopathological parameters of 115 OSCCs and
97 dysplasia patients are summarized in Table 1. The
median age of patients with OSCCs was 61 years (range
30 – 92) and dysplasia was 60 years (range 30 – 88).
AJCC pTNM stages III and IV comprised of a large pro-
portion of tumors in the study cohort.
Immunohistochemical analysis of Ep-ICD and EpEx
expression in oral tissues
To determine the clinical significance of Ep-ICD and
EpEx in development of oral cancer, its expression was
analyzed in OSCC, oral dysplasia and histologically nor-
mal tissues and the findings are summarized in Table 2.
Representative photomicrographs of Ep-ICD and EpEx
immunostaining in normal oral tissue, oral dysplasia
and OSCC are presented in Figs. 1 and 2 respectively.
Figure 1a shows predominantly Ep-ICDCyt staining in
normal oral mucosa with some of the stromal compo-
nents also showing immunostaining, increased cyto-
plasmic and nuclear staining is observed in dysplasia
(Fig. 1b) and OSCC also shows cytoplasmic and nuclear
staining (Fig. 1c), while a known OSCC showing Ep-
ICDNuc and Ep-ICDCyt was used as a negative control
(Fig. 1d), where the primary antibody was replaced by
isotype specific IgG and no immunostaining was ob-
served. No detectable EpExMem immunopositivity was
observed in normal oral mucosa (Fig. 2a), increased
EpExMem immunostaining was observed in dysplasia
(Fig. 2b), and reduced EpExMem staining was observed
in OSCC (Fig. 2c), while no detectable EpExMem im-
munostaining was observed in OSCC tissue section
Table 1 Clinicopathological characteristics of OSCC patients




Dysplasia (N = 97) N (%)
Age years (range, median) 30–88, 60
Gender
Male 51 (53 %)
Female 46 (47 %)
Follow-up outcome
Positive 22 (23 %)
Negative 61 (63 %)
Data not available 14 (14 %)
OSCC (n = 115)
Age years (range, median) 30–92, 61
Sex
Male 73 (63 %)
Female 42 (37 %)
AJCC pTNM classification
I 21 (18 %)
II 19 (17 %)
III 23 (20 %)
IV 35 (30 %)
Unknown 17 (15 %)
Extra capsular invasion
Positive 18 (16 %)
Negative 97 (84 %)
Perineural involvement
Positive 33 (29 %)
Negative 82 (71 %)
Vascular involvement
Positive 16 (14 %)
Negative 99 (86 %)
Follow-up outcome
Positive 32 (28 %)
Negative 61 (53 %)
Data not available 22 (19 %)
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used as negative control where the primary antibody
was replaced by isotype specific IgG (Fig. 2d).
Significant increase in Ep-ICDNuc (p = 0.013) and
EpExMem (p < 0.001) was observed in dysplasia as
compared to normal oral tissues (Table 2). OSCC pa-
tients also showed significant increase in Ep-ICDNuc
(p < 0.001) as compared to normal oral tissues (Table 2).
The loss of EpExMem has been correlated with epithelial-
mesenchymal transition and increased aggressive pheno-
type as well as cancer progression. Hence we compared
the expression of EpEx and Ep-ICD between dysplasia
and OSCC. Notably, significant loss of EpExMem was
Table 2 Analysis of Ep-ICD and EpEx expression in Normal oral mucosa, Dysplasia and OSCC
Comparison with normal tissues Comparison with dysplastic tissues
N n % p-value O.R 95 % C.I. p-value O.R 95 % C.I.
Ep-ICD Nuclear
Normal 105 38 36.19
Dysplasia 97 52 53.61 0.013 2.037 1.16–3.58
OSCC 115 98 85.22 <0.001 10.164 5.30–19.49 <0.001 4.99 2.60–9.57
Ep-ICD Cyto
Normal 105 87 82.86
Dysplasia 97 81 83.51 0.90 1.05 0.50–2.19
OSCC 115 92 80 0.59 0.83 0.42–1.64 0.512 0.79 0.39–1.60
EpEX membrane
Normal 105 15 14.29
Dysplasia 97 37 38.14 <0.001 3.70 1.87–7.33
OSCC 115 28 24.35 0.06 1.93 0.97–3.86 0.03 0.52 0.29–0.94
Fig. 1 Immunohistochemical analysis of Ep-ICD in oral tissues. Paraffin-embedded sections of histologically normal mucosa, oral dysplasia and
OSCC were stained using anti-Ep-ICD monoclonal antibody as described in Methods section. Panel presents representative photomicrographs of
Ep-ICD staining. a Shows predominantly Ep-ICDCyt staining in normal oral mucosa with some stromal staining; b Increased cytoplasmic and nuclear
staining is observed in dysplasia; c OSCC also shows cytoplasmic and nuclear staining; d No immunostaining was observed in tissue sections used as
negative controls where the primary antibody was replaced by isotype specific IgG; while a known OSCC showing Ep-ICDNuc and Ep-ICDCyt was used
as a positive control (Data not shown); (a, b, c, d, original magnification x 200)
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observed in OSCC as compared to dysplasia (p = 0.03)
(Table 2). The final IHC scores based on the multiplica-
tion of the score of percentage positivity and intensity
of each of the tissue section also gave similar results
(Table 3).
Prognostic analysis of Ep-ICD and EpEx in oral dysplasia
and OSCC patients
The relationships between the alterations in expression
of Ep-ICDNuc, overall Ep-ICD (combination of Ep-ICDNuc
and Ep-ICDCyt), EpExMem and a combination of Ep-ICDNuc
Fig. 2 Immunohistochemical analysis of EpEx in oral tissues. Paraffin-embedded sections of histologically normal mucosa, oral dysplasia and OSCC
were stained using anti-EpEx monoclonal antibody as described in Methods section. Panel represents (a) normal oral mucosa showing no detectable
EpExMem immunostaining; b Oral dysplasia showing intense EpExMem staining; c OSCC section illustrating reduced EpExMem in tumor cells; d OSCC
section used as a negative control, showing no EpEx immunostaining in tumor cells where the primary antibody was replaced by isotype specific IgG
(A-D original magnification x 200)
Table 3 Analysis of Ep-ICD(%positivity*intensity) and EpEx(%positivity*intensity) expression in Normal oral mucosa, Dysplasia and OSCC
Comparison with normal tissues Comparison with dysplastic tissues
N n % p-value O.R 95 % C.I. p-value O.R 95 % C.I.
Ep-ICD Nuclear
Normal 105 38 36.19
Dysplasia 97 52 53.61 0.013 2.037 1.16–3.58
OSCC 115 98 85.22 <0.001 10.164 5.30–19.49 <0.001 4.99 2.60–9.57
Ep-ICD Cyto
Normal 105 87 82.86
Dysplasia 97 81 83.51 0.90 1.05 0.50–2.19
OSCC 115 92 80 0.59 0.83 0.42–1.64 0.512 0.79 0.39–1.60
EpEX membrane
Normal 105 15 14.29
Dysplasia 97 37 38.14 <0.001 3.70 1.87–7.33
OSCC 115 28 24.35 0.06 1.93 0.97–3.86 0.03 0.52 0.29–0.94
Cut-offs: Ep-ICDNuc – 1, Ep-ICD Cyto – 3 and EpEX Membrane – 1
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and EpExMem with clinical outcome of oral dysplasia and
OSCC patients were determined by Kaplan Meier survival
analysis over a follow up period of 60 months to investigate
their utility as prognostic markers for dysplasia and OSCC.
Dysplasia patients with increased overall Ep-ICD had sig-
nificantly shorter mean cancer free survival of 47 months
as compared to patients with low overall Ep-ICD (mean
DFS = 57.5 months; p = 0.044, Fig. 3a). OSCC patients with
increased combination of Ep-ICDNuc and EpExMem had
significantly reduced mean DFS of 33.7 months as com-
pared to patients with low Ep-ICDNuc and EpExMem score
(mean DFS = 46.3 months; p = 0.018, Fig. 3b). Among the
OSCC cases, Cox multivariate regression analysis showed
combination of Ep-ICDNuc and EpExMem and Extra capsu-
lar invasion to be the most important prognostic markers
for reduced DFS (p = 0.003, HR = 4.01, C.I. = 1.64–9.83
and p = 0.004, HR = 4.14, C.I. = 1.56–10.96, respectively,
Table 4).
Discussion
Ever since the regulated intramembranous proteolysis of
EpCAM was described as a novel mechanism of trig-
gering oncogenic signaling by Maetzel et al. [34], inves-
tigation of Ep-ICD expression in human epithelial cancers
for determination of its potential relevance to assist in the
management of many human epithelial cancers has been
undertaken. Our earlier preliminary study reported fre-
quent Ep-ICDNuc and Ep-ICDCyt expression in ten dif-
ferent epithelial cancers, including a small number of
head and neck cancers [36]. This first report did not
examine the correlation of Ep-ICDNuc expression with
clinical parameters or its prognostic utility in these can-
cers, nor did it evaluate the expression of these proteins
in premalignant oral lesions with dysplasia prior to can-
cer development. The current study assessed the dy-
namic changes in Ep-ICD and EpEx expression in oral
normal mucosa, dysplasia and OSCC to assess their
relevance in oral tumorigenesis and potential suitability
as marker in predicting clinical course and aggressive-
ness of head and neck cancer. Although expression of
the full length EpCAM protein has been widely investi-
gated in human malignancies, the expression and sub-
cellular localization of its intracellular domain Ep-ICD
has not been well characterized in clinical specimens.
Our study demonstrated differences in expression of
Ep-ICD and EpEx between normal, dysplastic and ma-
lignant oral tissues and their relationship with disease
prognosis, providing valuable information as to their
suitability as potential biological markers. Given the
interest in the therapeutic potential of EpCAM targeted
therapies in cancer management and the limited under-
standing of the role and expression pattern of Ep-ICD
in oral cancer, our study helps to shed light on this
widely-studied, yet not fully understood protein. Further-
more, our study is the first in-depth characterization of
Ep-ICD expression in oral dysplasia and OSCC.
The increased expression of EpExMem and Ep-ICDNuc
in dysplasia in comparison with normal tissues suggests
Fig. 3 Kaplan Meier survival analysis of Ep-ICD in Oral Dysplasia and OSCC patients. a Dysplasia patients with increased overall (nuclear and cytoplasmic)
Ep-ICD score had significantly reduced mean cancer free survival of 47 months as compared to patients with low overall Ep-ICD score (mean cancer free
survival = 57.5 months; p= 0.044); b OSCC patients with increased Ep-ICDNuc and EpExMem score had significantly reduced mean disease free survival (DFS)
of 33.7 months as compared to patients with decreased Ep-ICDNuc and EpExMem score (mean DFS = 46.3 months; p= 0.018)
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an overall upregulation of EpCAM expression as well as
its increased proteolysis that would account for in-
creased Ep-ICDNuc. Interestingly, the increased regulated
intramembranous proteolysis of EpCAM resulting in re-
lease of its cytoplasmic domain, Ep-ICD in colon carcin-
oma and its subsequent translocation to the nucleus has
been demonstrated to trigger oncogenic signaling [34].
In our present study we observed increased Ep-ICDNuc
in dysplasia and further increase in OSCC. Importantly,
our findings on the follow up of patients with oral dys-
plasia demonstrate that patients with increased overall
Ep-ICD (nuclear and cytoplasmic) developed cancer
within a shorter time period as compared to those who
did not show increased Ep-ICD; these observations are
in accord with the proposed oncogenic function of Ep-
ICDNuc. Our findings are novel and of considerable
clinical relevance in view of the fact that early predic-
tion of malignant potential of oral epithelial dysplasia
is crucial for precise clinical management of patients
in early premalignant stages, prior to development of
frank cancer.
In an earlier study, we reported that Ep-ICDNuc accu-
mulation predicted poor prognosis in thyroid carcinomas
and was elevated in patients with anaplastic tumors [36].
Notably, we observed that OSCC patients showing in-
creased EpExMem and Ep-ICDNuc had reduced disease free
survival and poor prognosis as compared to patients who
did not show this increase, suggesting that dynamic
changes in EpExMem and Ep-ICDNuc must be taken into
account collectively to assess their prognostic utility in
OSCC. It is important to note that our recent studies on
prognostic relevance of Ep-ICDNuc and Ep-ICDCyt and
EpEx in breast cancer and prostate cancer also demon-
strated context dependent adaption of Ep-ICD in different
human cancers [42, 43]. The recent report on EpCAM
expression in early systemic esophageal cancer also sup-
ports our findings [16]. A dynamic expression of EpCAM
was shown in esophageal cancer throughout tumor
progression, where EpCAMhigh phenotypes correlated
with proliferative stages, whereas EpCAMlow/negative
phenotypes were associated with migration, invasion and
dissemination, suggesting that differing expression levels
of EpCAM occur during cancer progression and must be
taken into consideration for therapeutic approaches and
during clinical retrieval of disseminated tumor cells [29].
The discovery of the tumor-suppressive properties of
EpCAM in some cancers has surprised many researchers,
given its association with poor prognosis in many other
cancers. Some studies have suggested the tumor micro-
environment may be an important factor in dictating
whether EpCAM will promote or inhibit tumor progres-
sion, particularly given its ability to mediate homophilic
adhesive interactions between cells [5]. Furthermore, regu-
lated intramembrane proteolysis of EpCAM and the asso-
ciated oncogenic signalling by Ep-ICD may shed light on
some of these observations as additional protein-protein
interactions are uncovered [8, 44]. Recently, the endoplas-
mic reticulum aminopeptidase 2 (ERAP2), a proteolytic
enzyme set in the endoplasmic reticulum (ER) has been
shown to co-localize with EpCAM in the cytoplasm/ER
where it plays a central role in the trimming of peptides
for presentation by MHC class I molecules. This associ-
ation between EpCAM and ERAP2 suggests a new mech-
anism of EpCAM processing and regulation of antigen
presentation in breast cancer [45].
A major challenge is to predict the prognosis of OSCC
patients effectively after completion of their primary treat-
ment. In this context our study assumes importance, be-
cause of its retrospective nature, the large set of patients
representing different stages of OSCC and long-term
follow-up analysis. Our study uniquely based on sub-
cellular compartment analysis of Ep-ICD and EpEx ex-
pression for correlation with clinical outcome, gave a
more comprehensive insight into the clinical relevance
of alterations in sub-cellular localization of a protein on
disease outcome. Hence, our study emphasizes the
Table 4 Kaplan-Meier survival analysis and Multivariate Cox regression analysis for OSCC patients




Hazard’s ratio (H.R.) 95 % C.I.
Ep-ICDNuc
+ 0.078 0.049 0.35 0.12–0.98
EpExMembrane
+ 0.302 0.189 —— ——
Ep-ICDNuc + EpExMembrane
+ 0.016 0.003 4.01 1.64–9.83
Age 0.33 0.026 —— ——
T classification 0.63 0.913 —— ——
Nodal classification 0.041 0.633 —— ——
Clinical stage 0.225 0.293 —— ——
Extra capsular invasion <0.001 0.004 4.14 1.56–10.96
Perineural involvement 0.828 0.102 —— ——
Vascular involvement 0.355 0.552 —— ——
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importance of sub-cellular compartmental analysis of
Ep-ICD and EpEx in membrane, cytoplasm and nucleus
as compared to the overall protein expression reported
in most of the earlier studies.
Conclusions
In conclusion, we demonstrate overexpression of Ep-ICD
occurs in early stages, in oral dysplasia and is sustained in
cancer. Increased Ep-ICD in patients with oral dysplasia
has the potential to serve as a biomarker to stratify pa-
tients at high risk of cancer development and enable early
intervention in these patients for precise rigorous disease
management prior to development of frank malignancy.
Importantly, the combination of Ep-ICDNuc and EpExMem
can serve as a predictor of risk of recurrence in OSCC
patients suggesting its potential to act as a prognostic
marker to identify oral cancer patients who need more
personalized post-treatment management.
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